Hosted on MSN22h
HeartBeam submits 510(k) application to FDA for ECG software
HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five ...
HeartBeam seeks FDA nod for ECG synthesis software
SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...
Biomednewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Submits FDA Application For 12-Lead ECG Synthesis Software
HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...
Wall Street Journal3y
Heartbeam Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
BioWorld1mon
FDA clearance adds glow to Heartbeam prospects
Heartbeam Inc. received U.S. FDA 510(K) clearance for its portable, non-invasive electrocardiogram system that enables on-the-go recording of heart signals. The cable-free, credit card-sized device ...
Joplin Globe7d
Blaize Appoints Yoshiaki Fujimori and George de Urioste to Board of Directors
Blaize Holdings, Inc. (NASDAQ:BZAI), a provider of purpose-built, artificial intelligence (AI)-enabled edge computing solutions, today announced the appointment of George de Urioste and Yoshiaki ...